Aug 2026· Cancer Investigation· pp.
1-22
· 0 citations· 131 references
Medicine
TL;DR
The findings support a precision immuno-oncology framework based on composite biomarkers, longitudinal monitoring, and adaptive treatment selection matched to dominant resistance mechanisms.
Abstract
Immune checkpoint inhibitors (ICIs) targeting PD-1, PD-L1, CTLA-4, and LAG-3 have transformed cancer therapy, but resistance limits durable benefit. This integrative review summarizes primary, adaptive, and acquired resistance driven by tumor-intrinsic defects, suppressive tumor microenvironmental programs, and host-related factors. We discuss mechanism-based strategies to overcome resistance, including combination immunotherapy, antiangiogenic treatment, TGF-β targeting, myeloid reprogramming, epigenetic and metabolic interventions, microbiome modulation, and cellular or vaccine-based approaches. The findings support a precision immuno-oncology framework based on composite biomarkers, longitudinal monitoring, and adaptive treatment selection matched to dominant resistance mechanisms.
Immunotherapy, particularly immune checkpoint inhibitors (ICIs), has transformed the treatment landscape for advanced esophageal cancer (EC). Nevertheless, clinical benefits are constrained by primary and acquired resistance driven by a dynamic immunosuppressive tumor microenvironment (TME), extensive metabolic reprogr...
Y. Pang, Pan-Pan Jiang, Ke Liu et al.· Frontiers in Immunology· 0 citations
This review integrates the major tumor-intrinsic and tumor-extrinsic mechanisms that drive ICI resistance, including defective antigen presentation, impaired interferon signaling, oncogenic and epigenetic immune escape programs, metabolic rewiring, suppressive myeloid and stromal circuits, abnormal vasculature, and pro...
R. Karataş, Yaren Alras, Sarenur Teki̇ner et al.· Immunologic research· 0 citations
This review presents a systematic synthesis of the principal tumor immunotherapy strategies and their corresponding resistance mechanisms, finding that combination therapies and personalized treatment strategies grounded in TME profiling and biomarkers represent critical future directions.
This position article synthesizes key barriers in ICI therapy while highlighting emerging opportunities to refine patient selection, improve safety, and enhance therapeutic durability, position the field to move beyond the current plateau toward a more precise, effective, and patient-centered era of immuno-oncology.
Joud Hajjar, B. Stephen, A. Aaroe et al.· Journal of Immunotherapy and...· 1 citation
Immune checkpoint blockade targeting PD-1/PD-L1 has reshaped cancer therapy across multiple tumor types. However, primary and acquired resistance remain major barriers to durable clinical benefit. Increasing evidence indicates that immunotherapy resistance is not driven by isolated molecular alterations, but by coordin...
Chao Wang, Dong Yang· Frontiers in Cell and Develo...· 0 citations
Programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) immune checkpoint inhibitors have redefined the therapeutic landscape of advanced melanoma, establishing a first-line standard of care that markedly prolongs patient survival. Nevertheless, primary and acquired resistance remain the principal barr...
Yu-Hua Li, Jing Wu, Wei-Ming Liao et al.· Frontiers in Pharmacology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
